Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes

Diabetes Care

Volumn 31, Issue 7, 2008, Pages 1461-1466

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; EXENDIN 4; INCRETIN; METFORMIN; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFECT; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; LOW FAT DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PROTEIN DIET; RISK FACTOR; TREATMENT FAILURE; DIABETIC DIET; LOW CALORY DIET; REVIEW;

DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DIET, REDUCING; HUMANS; OBESITY; PREDIABETIC STATE;

EID: 49649083578     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-zb07     Document Type: Article

References (56)

1. American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596-615, 2008
2. Sloan FA, Bethel MA, Ruiz D Jr, Shea AH, Feinglos MN: The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 168:192-199, 2008
3. Kendall DM, Bergenstal RM: Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care 7 (Suppl.):S327-S343, 2001
4. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K: Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334:299, 2007
5. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
7. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiu- kaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673-1679, 2006
8. The Look AHEAD Research Group: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 30:1374-1383, 2007
9. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group: The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142:323-332, 2005
10. Eddy DM, Schlessinger L, Kahn R: Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143:251-264, 2005
11. Christian JG, Bessesen DH, Byers TE, Christian KK, Goldstein MG, Bock BC: Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and lose weight. Arch Intern Med 168:141-146, 2008
12. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE: Meta-analysis: metformin treatment in individuals at risk for diabetes mellitus. Am J Med 121:149-157, 2008
13. The DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR: Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551-1562, 2006
14. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105, 2006
15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486 -494, 2003
16. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimon- abant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672, 2006
17. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized studyoforlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155-161, 2004
18. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B: Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753-759, 2007
19. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:316-323, 2008
20. Heikes KE, Eddy DM, Arondekar B, Schlessinger L: Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care 31:1040-1045, 2008
21. Kochar J, Djousse L, Gaziano JM: Breakfast cereals and risk of type 2 diabetes in the physicians' health study I. Obesity 15: 3039-3044, 2007
22. Priebe MG, van Binsbergen JJ, de Vos R, Vonk RJ: Whole grain foods for the prevention of type 2 diabetes mellitus. Cochrane Database Syst Rev 23:CD006061, 2008
23. Lane JD, Feinglos MN, Surwit RS: Caffeine increases ambulatory glucose and postprandial responses in coffee drinkers with type 2 diabetes. Diabetes Care 31: 221-222, 2008
24. Smith B, Wingard DL, Smith TC, Kritz-Silverstein D, Barrett-Connor E: Does coffee consumption reduce the risk of type 2 diabetes in individuals with impaired glucose? Diabetes Care 29:2385-2390, 2006
25. Lutsey PL, Steffen LM, Stevens J: Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. Circulation 117: 754-761, 2008
26. Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, D'Agostino RB, Ga- ziano JM, Vasan RS: Soft drink consumption and risk of developing cardio-metabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 116:480-488, 2007
27. Bravata DM, Smith-Spangler C, Sun- daram V, Gienger AL, Lin N, Lewis R, Stave CD, Olkin I, Sirard JR: Using pedometers to increase physical activity and improve health: a systematic review. JAMA 298:2296 -2304, 2007
28. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud'homme D, Fortier M, Reid RD, Tul- loch H, Coyle D, Phillips P, Jennings A, Jaffey J: Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. AnnInternMed 147:357-369, 2007
29. Yaggi HK, Araujo AB, McKinlayJB: Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care 29: 657-661, 2006
30. Brand-Miller J, Hayne S, Petocz P, Colagiuri S: Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 26:2261-2267, 2003
31. Ma Y, Pagoto SL, Griffith JA, Merriam PA, Ockene IS, Hafner AR, Olendzki BC: A dietary quality comparison of popular weight-loss plans. J Am Diet Assoc 107: 1786-1791, 2007
32. Gardner CD, Kiazand A, Alhassan S, Kim S, Stafford RS, Balise RR, Kraemer HC, King AC: Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 297:969-977, 2007
33. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, Bucher HC: Effects of low-carbohydrate vs low- fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 166:285-293, 2006
34. Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams M, Gracely EJ, Samaha FF: The effects of low- carbohydrate versus conventional weight loss diets in severely obese adults: one- year follow-up of a randomized trial. Ann Intern Med 140:778-785, 2004
35. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L: A low- carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 348: 2074-2081, 2003
36. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, McGrory J, Gracely EJ, Rader DJ, Samaha FF: A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med 117:398-405, 2004
37. Opperman AM, Venter CS, Oosthuizen W, Thompson RL, Vorster HH: Metaanalysis of the health effects of using the glycaemic index in meal-planning. Br J Nutr 92:367-81, 2004
38. White AM, Johnston CS, Swan PD, Tjonn SL, Sears B: Blood ketones are directly related to fatigue and perceived effort during exercise in overweight adults adhering to low-carbohydrate diets for weight loss: a pilot study. J Am Diet Assoc 107:1792-1796, 2007
39. Levine JA: Non-exercise activity thermo- genesis (NEAT). Best Pract Res Clin Endocrinol Metab 16:679-702, 2002
40. Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN, Maratos-Flier E, Flier JS: Leptin regulation of the mesoaccum- bens dopamine pathway. Neuron 51:811-822, 2006
41. Flier JS, Cook KS, Usher P, Spiegelman BM: Severely impaired adipsin expression in genetic and acquired obesity. Science 237:405-408, 1987
42. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS: Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 19:339-344, 1992
43. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543-546, 1995
44. Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB, Flier JS: Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1:1311-1314, 1995
45. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295, 1996
46. Frederich RC, Lollmann B, Hamann A, Napolitano-Rosen A, Kahn BB, Lowell BB, Flier JS: Expression of ob mRNA and its encoded protein in rodents: impact ofnu- trition and obesity. J Clin Invest 96:1658-1663, 1995
47. El-Haschimi K, Pierroz DD, Hileman SM, Bjørbaek C, Flier JS: Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. JClin Invest 105:1827-1832, 2000
48. Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bj0rbaek C, Flier JS: Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10:734-748, 2004
49. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, Maratos-Flier E: A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380:243-247, 1996
50. Kokoeva MV, Yin H, Flier JS: Neurogen- esis in the hypothalamus of adult mice: potential role in energy balance. Science 310:679-683, 2005
51. Graef I, Gibbons DM: Salicylates and carbohydrate metabolism. Diabetes 9:416-418, 1960
52. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956-959, 1994
53. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicy- late inhibit the activity of I(kappa)B kinase-beta. Nature 396:77-80, 1998
54. Fleischman A, Shoelson SE, Bernier R, Goldfine AB: Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31:289-294, 2008
55. Garg A, Grundy SM: Cholestyramine therapy for dyslipidemia in non-insulin- dependent diabetes mellitus: a short- term, double-blind, crossover trial. Ann InternMed 121:416-422, 1994
56. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL: Results of the glucose- lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29:74-83, 2007